Table 3.
Treatment outcomes in patients with each sequential chemotherapy
| FFX-GnP (n = 120) | GnP-FFX (n = 61) | P value | FFX-GnP (n = 53) | GnP-FFX (n = 59) | P value | |
|---|---|---|---|---|---|---|
| Treatment duration (months) | 12.0 (7.6–18.1) | 11.7 (7.6–19.4) | 0.945 | 12.0 (8.0–22.3) | 11.7 (7.4–20.0) | 0.714 |
| Best response in second-line treatment | 0.86 | 0.69 | ||||
| CR | 1 (0.8) | 0 (0) | 1 (1.9) | 0 (0) | ||
| PR | 19 (15.8) | 10 (16.4) | 7 (13.2) | 10 (16.9) | ||
| SD | 61 (50.8) | 29 (47.5) | 27 (50.9) | 28 (47.5) | ||
| PD | 39 (32.5) | 22 (36.1) | 18 (34.0) | 21 (35.6) | ||
| Response rates in second-line treatment | ||||||
| DCR | 81 (67.5) | 39 (63.9) | 0.631 | 35 (66.0) | 38 (64.4) | 0.86 |
| ORR | 20 (16.7) | 10 (16.4) | 0.963 | 8 (15.1) | 10 (16.9) | 0.79 |
| Third-line chemotherapy | 47 (39.2) | 29 (47.5) | 0.508 | 16 (30.2) | 28 (47.5) | 0.14 |
| Other 5-FUa | 46 | 6 | 1 | 6 | ||
| Other gemcitabineb | 1 | 21 | 15 | 20 | ||
| Other (clinical trial, SBRT) | 0 | 2 | 0 | 2 | ||
FFX FOLFIRINOX, GnP gemcitabine plus nab-paclitaxel, AEs adverse events, CR complete response, PR partial response, SD stable disease, PD progression of disease, ORR objective response rate, DCR disease control rate, 5-FU 5-fluorouracil, SBRT stereotactic body radiotherapy, NAPOLI nanoliposomal irinotecan plus 5-FU/lecovorin, iFAM infusional 5-FU plus doxorubicin and mitomycin-C
aIncluded the NAPOLI, iFAM, tegafur/gimestat/otastat potassium, capecitabine, and CCRT with 5-FU or capecitabine regimens
bIncluded gemcitabine, gemcitabine plus erlotinib